Partnerships

Partnerships

Our Partnering Strategy

We seek and encourage meaningful partnerships and collaborations with leading pharmaceutical and biopharmaceutical organizations, research institutions, government agencies and foundations to further the impact of our proven technology.

Diversified Pipeline

We seek to establish partnerships for our pipeline programs earlier in the R&D process to accelerate development and bring effective medicines to people who will benefit. Our focus is on high-value areas of significant unmet medical need, compelling scientific rationale and strong commercial potential.

Matrix-M® Adjuvant

Matrix-M represents a significant partnership opportunity as it can facilitate the development of new best-in-class vaccines or improve existing vaccines.

Working Together

Sanofi

Our collaboration with Sanofi includes co-commercialization of our COVID-19 vaccine as well as development and commercialization of combination products containing (1) our COVID-19 vaccine and Sanofi’s seasonal influenza vaccine and (2) our COVID-19 vaccine and Sanofi’s non-influenza vaccines. Sanofi also has a non-exclusive license to develop and commercialize products containing Novavax’s Matrix-M® adjuvant.

Takeda

Takeda has an exclusive license to develop, manufacture and commercialize Novavax’s COVID-19 vaccine in Japan.

Serum Institute of India

SII has an exclusive license to market Novavax’s COVID-19 vaccine in India. Novavax provides Matrix-M for SII’s commercialization of its R21 malaria vaccine.

SK Bioscience

SK bioscience has an exclusive license to supply and commercialize Novavax’s COVID-19 vaccine in Korea.

About Us

We tackle some of the world's most significant health challenges by leveraging our scientific expertise and a cutting-edge technology platform that includes protein-based nanoparticles and Matrix-M adjuvant.


Our Pipeline

Our protein-based nanoparticle technology and Matrix-M® adjuvant are the foundation of our diverse vaccine pipeline.


Science & Technology

Our technology platform combined with our vaccine expertise is the fuel for future innovation and partnerships.